RecruitingNot ApplicableNCT04250493

Insulin Resistance in Multiple System Atrophy


Sponsor

University Hospital, Bordeaux

Enrollment

124 participants

Start Date

Oct 28, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.


Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether people with multiple system atrophy (MSA) — a rare brain disorder affecting movement and automatic body functions — have problems with insulin resistance (the body not responding properly to insulin), and whether this is linked to changes in the brain. **You may be eligible if:** - You have a diagnosis of "possible" or "probable" multiple system atrophy (MSA) - You are over 30 years old - You are covered by the national health system (in France) - Healthy volunteers over 30 without neurological disorders are also eligible for comparison **You may NOT be eligible if:** - You have diabetes - You take corticosteroids, estrogens, atypical antipsychotics, or antiretroviral medications - You are pregnant or breastfeeding - Your score on a brief memory test (MoCA) is very low (21 or below) - You cannot have an MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALHomeostasis Model Assessment of insulin resistance (HOMA)

Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index

BEHAVIORALMOntreal Cognitive Assessment (MoCA)

Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)

BEHAVIORALClinical characteristics of AMS patients

Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)

PROCEDUREBrain Magnetic Resonance Imaging (MRI)

Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume

BIOLOGICALBlood sampling

Optional blood sampling for the constitution of a biological collection


Locations(1)

CHU de Bordeaux

Bordeaux, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04250493


Related Trials